STAT3 and non-small cell lung carcinoma: Taken together, in the present study we demonstrated that W2014-S, as a novel STAT3 inhibitor, effectively inhibited STAT3 signaling with potent anti-tumor activities in human lung cancer, and enhanced the sensitivity of resistant NSCLC to gefitinib in vitro and in vivo.